首页> 外文期刊>JAMA: the Journal of the American Medical Association >Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial.
【24h】

Effect of DHEA on abdominal fat and insulin action in elderly women and men: a randomized controlled trial.

机译:DHEA对老年男女腹部脂肪和胰岛素作用的影响:一项随机对照试验。

获取原文
获取原文并翻译 | 示例
       

摘要

CONTEXT: Dehydroepiandrosterone (DHEA) administration has been shown to reduce accumulation of abdominal visceral fat and protect against insulin resistance in laboratory animals, but it is not known whether DHEA decreases abdominal obesity in humans. DHEA is widely available as a dietary supplement without a prescription. OBJECTIVE: To determine whether DHEA replacement therapy decreases abdominal fat and improves insulin action in elderly persons. DESIGN AND SETTING: Randomized, double-blind, placebo-controlled trial conducted in a US university-based research center from June 2001 to February 2004. PARTICIPANTS: Fifty-six elderly persons (28 women and 28 men aged 71 [range, 65-78] years) with age-related decrease in DHEA level. INTERVENTION: Participants were randomly assigned to receive 50 mg/d of DHEA or matching placebo for 6 months. MAIN OUTCOME MEASURES: The primary outcome measures were 6-month change in visceral and subcutaneous abdominal fat measured by magnetic resonance imaging and glucoseand insulin responses to an oral glucose tolerance test (OGTT). RESULTS: Of the 56 men and women enrolled, 52 underwent follow-up evaluations. Compliance with the intervention was 97% in the DHEA group and 95% in the placebo group. Based on intention-to-treat analyses, DHEA therapy compared with placebo induced significant decreases in visceral fat area (-13 cm2 vs +3 cm2, respectively; P = .001) and subcutaneous fat (-13 cm2 vs +2 cm2, P = .003). The insulin area under the curve (AUC) during the OGTT was significantly reduced after 6 months of DHEA therapy compared with placebo (-1119 muU/mL per 2 hours vs +818 muU/mL per 2 hours, P = .007). Despite the lower insulin levels, the glucose AUC was unchanged, resulting in a significant increase in an insulin sensitivity index in response to DHEA compared with placebo (+1.4 vs -0.7, P = .005). CONCLUSION: DHEA replacement could play a role in prevention and treatment of the metabolic syndrome associated with abdominal obesity.
机译:背景:已证明脱氢表雄酮(DHEA)可以减少实验动物的腹部内脏脂肪蓄积并保护其抵抗胰岛素抵抗,但尚不知道DHEA是否能减轻人的腹部肥胖。 DHEA无需处方即可广泛用作膳食补充剂。目的:确定DHEA替代疗法是否可以减少老年人的腹部脂肪并改善胰岛素作用。设计与地点:2001年6月至2004年2月在美国大学研究中心进行的随机,双盲,安慰剂对照试验。参与者:56名老年人(28名女性和28名71岁的男性[范围:65- 78]岁),DHEA水平与年龄相关。干预:参与者被随机分配接受50 mg / d的DHEA或匹配的安慰剂治疗,为期6个月。主要观察指标:主要观察指标是通过磁共振成像测量的内脏和皮下腹部脂肪的6个月变化以及口服葡萄糖耐量试验(OGTT)的葡萄糖和胰岛素反应。结果:在56名男女中,有52名接受了随访评估。 DHEA组对干预的依从性为97%,安慰剂组为95%。根据意向性治疗分析,与安慰剂相比,DHEA治疗可显着减少内脏脂肪面积(分别为-13 cm2和+3 cm2; P = .001)和皮下脂肪(-13 cm2对+2 cm2,P)。 = .003)。与安慰剂相比,DHEA治疗6个月后,OGTT曲线下的胰岛素面积(AUC)显着降低(-1119 muU / mL每2小时vs +818 muU / mL每2小时,P = .007)。尽管胰岛素水平较低,但与安慰剂相比,对DHEA的葡萄糖AUC并未发生改变,导致胰岛素敏感性指数显着增加(+1.4 vs -0.7,P = .005)。结论:脱氢表雄酮替代可以预防和治疗腹部肥胖相关的代谢综合征。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号